MA+AZA for Newly Diagnosed AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of two medicines (called MA+AZA) for people who have just been diagnosed with acute myeloid leukemia (AML). It aims to see if this treatment can help control the disease and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have been newly diagnosed with AML (confirmed by a bone marrow test).
- Your liver and kidneys must be working well (based on simple blood tests).
- Your heart function must be strong (heart pump strength 50% or more).
- You should be in good enough health to walk around and take care of yourself (ECOG score 0-2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing new drug combinations for people with newly diagnosed, high-risk AML who have not yet started treatment. It aims to find more effective therapies for this aggressive form of leukemia.
This trial tests whether adding a chemotherapy drug (azacitidine) along with donor immune cells can help prevent acute myeloid leukemia (AML) from coming back after a stem cell transplant. It is for people who had a half-matched (haploid) transplant and are at high risk for relapse.
This trial tests a combination of two drugs, SA and X, for people who have just been diagnosed with acute myeloid leukemia (AML) and have not yet received treatment (except hydroxyurea to lower white blood cells). The goal is to see if the combination works better than standard care.
This trial tests a new drug combination (bleximenib, venetoclax, and azacitidine) for people with a specific genetic type of AML who cannot receive strong chemotherapy. The goal is to see if this combination is safer and more effective.
This trial tests whether a combination of two drugs, chidamide and azacitidine (AZA), can help people with acute myeloid leukemia (AML) who still have small amounts of leukemia cells (called MRD) after a stem cell transplant. The goal is to see if this treatment can clear those leftover cells and lower the chance of the leukemia coming back.
This study tests a new drug called BL-M11D1 combined with standard chemotherapy (cytarabine + daunorubicin) or a targeted therapy (venetoclax + azacitidine) for people with newly diagnosed acute myeloid leukemia (AML). It aims to see if this combination is safe and effective.
Hear when a new Acute Myeloid Leukaemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.